Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Trending Now
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Breaking News
Surgical innovation in dry eye disease: Salivary gland transplant
Ağustos 27, 2025
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
OCT changes with low-level red light therapy for myopia in children
Ağustos 26, 2025
Alcon presenting at APACRS 2025
Ağustos 21, 2025
Breaking News
Popular Now
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the…
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
Collaborate With Us
Join forces with Ophthalmology News to reach a global community of eye care professionals. Whether you want to contribute an article, share research, or explore partnership opportunities, we’d love to hear from you.
Editor Choice
From lab to clinic: Advancing ophthalmic technology | Ophthalmology Times
Emerging diagnostic and surgical technologies are enhancing precision, improving efficiency, and shaping…
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its…
Eli Lilly to acquire Adverum Biotechnologies | Ophthalmology Times
Image credit: AdobeStock/jozefmicic The Eli Lilly and Company will acquire Adverum Biotechnologies,…
Positive phase 2 data for neoadjuvant darovasertib offers hope for unmet need in uveal melanoma | Ophthalmology Times
Image credit: AdobeStock/Christoph Burgstedt Positive results from the ongoing Phase 2 OptimUM-09…
Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times
(Image Credit: AdobeStock) The structural differences among newer second-generation anti-VEGF agents—and their…
What if? Ophthalmology without OCT – Part 3 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what…
Throwback Series: From epidemic to innovation in corneal surgery | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback”…
Regeneron receives another CRL for its Eyelea 8 mg | Ophthalmology Times
Regeneron has once again received a complete response letter (CRL) from the…
Cataract and refractive surgery: Trends, challenges, and innovations | Ophthalmology Times
Ongoing innovation in cataract and refractive surgery is driving improved precision, safety,…
Worth Reading
Meeting expectations with evolving technology
Ağustos 26, 2025
/ Patient Education, Research & Studies, Technology & Innovation, Treatments & Surgery
Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Ağustos 26, 2025
/ Industry News, Patient Education, Research & Studies, Treatments & Surgery
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Ağustos 26, 2025
/ Patient Education, Research & Studies
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
/ Patient Education, Research & Studies, Treatments & Surgery
Subscribe Now
Enter your email address below and subscribe to our newsletter